Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
Ceribell (Nasdaq: CBLL) will report its first quarter 2026 financial results after market close on Monday, May 11, 2026.
Rhea-AI Summary
Ceribell (Nasdaq: CBLL) will report its first quarter 2026 financial results after market close on Monday, May 11, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss results.
Investors can join by phone (domestic: (800) 715-9871; international: (646) 307-1963; access code 1880547) or via a live and archived webcast in the company's Investor Relations website at https://investors.ceribell.com/.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CBLL
On Apr 21, the first trading day after this news, CBLL closed 0.90% below the previous close.
Data tracked by StockTitan Argus for the Apr 21 session.
Key Figures
- Q4 2025 revenue
- $24.8M
- Fourth quarter 2025 results; +34% year-over-year growth
- FY 2025 revenue
- $89.1M
- Full-year 2025 results; +36% year-over-year growth
- Q4 2025 gross margin
- 87%
- Fourth quarter 2025 profitability metric
- FY 2025 gross margin
- 88%
- Full-year 2025 profitability metric
- FY 2025 operating expenses
- $136.7M
- Full-year 2025 operating cost base; +42% year-over-year
- FY 2025 net loss
- $53.4M
- Full-year 2025 bottom-line result
- Cash & securities
- $159.3M
- Cash and marketable securities at end of 2025
- 2026 revenue guidance
- $111M–$115M
- Company’s 2026 revenue outlook (~25%–29% growth)
Previous Earnings date Reports
-
Scheduled Q4 and full-year 2025 earnings release and conference call details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Monday, May 11, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 11, 2026.
Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 1880547. A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Investor Contact
Brian Johnston
Gilmartin Group
Investors@ceribell.com
Media Contact
Brian Price
Press@ceribell.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.